WADAs 2026 Prohibited List includes growth hormone releasing factors and secretagogues such as CJC-1295, Sermorelin, Tesamorelin, Ibutamoren/MK-677, and Ipamorelin
Active, not recruiting Atherosclerotic Cardiovascular Disease Drug: Obicetrapib Drug: Placebo Continuation Protocol for Obstructive Sleep Apnea (OSA) The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep
Center for Disease Control and Prevention *based on data from retail and mail-order prescription fills Projected GLP-1 market size over the next decade Source: Aggregate sources The Next M&A Wave While the first wave of GLP-1 dealmaking centered on pharmaceutical assets, the next is likely to extend well beyond the drug itself
Heres what the clinical data actually says
Monophasic cellular blue nevi may be large and densely cellular with fascicles of spindle cells lacking a nested growth pattern
